Great Time for Pain Research: SMi’s Exclusive Interviews with Lotus Clinical Research and Centrexion Therapeutics
London, United Kingdom, April 14, 2018 --(PR.com)-- SMi Group reports: Ahead of 18th annual Pain Therapeutics Conference (London, 21 - 22 May) SMi Group have caught up with Neil Singla, Founder & Chief Scientific Officer at Lotus Clinical Research, LLC, Kerrie Brady - Chief Business Officer, Executive VP Strategy and Randall Stevens - Chief Medical Officer of Centrexion Therapeutics Corp to talk about industry and their vision on challenges and opportunities that lay ahead.
Kerrie Brady (Centrexion Therapeutics Corp) is identifying translation from preclinical models to clinical success as one the greatest research challenge; while Randall Stevens (Centrexion Therapeutics Corp) sees opportunities for analgesic therapeutics in working together with industry and academic partners to improve how we identify indications for molecules, get the risk:benefit ratio right, and improve regulatory environment.
SMi: Where do you see the greatest opportunities for analgesic therapeutics leaders?
Neil Singla (Lotus Clinical Research, LLC): We are in a great time for pain research. I’m seeing more great minds and more companies entering the field than at any other time in my 17-year history running Lotus. In light of the opioid crisis, the societal need for new therapies is so great that it’s created increased interest in the field from industry, academia and clinicians. I think researchers who develop an NCE with a novel mechanism of action in pain are in a position to change the world for the better, as are researchers who refine existing drugs to reduce potential harm.
These are snap-shots of the Q&A sessions and full transcripts can be found at http://www.pain-therapeutics.co.uk/prcom
Neil Singla will also be delivering a Keynote Address on Abdominoplasty as a novel analgesic model for acute soft tissue pain on the Day 1 of the Pain Therapeutics Conference.
Kerrie Brady and Randall Stevens are co-chairing this year's event and deliver presentations on Big Data role in drug development and the progress of CNTX-6970 study.
An elite speaker line-up is bound to inspire attendees through the exploration of innovative approaches and novel targets in analgesic medicine.
SMi Group also run Interactive Workshops on 23rd May alongside the Main event:
A: How Should the Likely Future Pain Therapeutic Landscape Inform Current Drug Development? By Prescient Healthcare Group
B: Clinical, Regulatory and Market Access Aspects in the Development of Medicinal Products intended for the Treatment of Pain in Europe and USA. By Pharma Design Ltd.
With preparations well underway for Pain Therapeutics Conference, organisers are reminding to make a note in the work schedule to attend this event which will offer an unparalleled expertise and insight into the analgesics medicine world.
For further information, visit http://www.pain-therapeutics.co.uk/prcom
Contact:
+44 (0)20 7827 6000
ldurneva@smi-online.co.uk
Twitter - @SMIpharm & #smipaintherapeutics
LinkedIn - SMi Pharma
Pain Therapeutics Conference | 21 - 22 May 2018 | London, UK
http://www.pain-therapeutics.co.uk/prcom
Kerrie Brady (Centrexion Therapeutics Corp) is identifying translation from preclinical models to clinical success as one the greatest research challenge; while Randall Stevens (Centrexion Therapeutics Corp) sees opportunities for analgesic therapeutics in working together with industry and academic partners to improve how we identify indications for molecules, get the risk:benefit ratio right, and improve regulatory environment.
SMi: Where do you see the greatest opportunities for analgesic therapeutics leaders?
Neil Singla (Lotus Clinical Research, LLC): We are in a great time for pain research. I’m seeing more great minds and more companies entering the field than at any other time in my 17-year history running Lotus. In light of the opioid crisis, the societal need for new therapies is so great that it’s created increased interest in the field from industry, academia and clinicians. I think researchers who develop an NCE with a novel mechanism of action in pain are in a position to change the world for the better, as are researchers who refine existing drugs to reduce potential harm.
These are snap-shots of the Q&A sessions and full transcripts can be found at http://www.pain-therapeutics.co.uk/prcom
Neil Singla will also be delivering a Keynote Address on Abdominoplasty as a novel analgesic model for acute soft tissue pain on the Day 1 of the Pain Therapeutics Conference.
Kerrie Brady and Randall Stevens are co-chairing this year's event and deliver presentations on Big Data role in drug development and the progress of CNTX-6970 study.
An elite speaker line-up is bound to inspire attendees through the exploration of innovative approaches and novel targets in analgesic medicine.
SMi Group also run Interactive Workshops on 23rd May alongside the Main event:
A: How Should the Likely Future Pain Therapeutic Landscape Inform Current Drug Development? By Prescient Healthcare Group
B: Clinical, Regulatory and Market Access Aspects in the Development of Medicinal Products intended for the Treatment of Pain in Europe and USA. By Pharma Design Ltd.
With preparations well underway for Pain Therapeutics Conference, organisers are reminding to make a note in the work schedule to attend this event which will offer an unparalleled expertise and insight into the analgesics medicine world.
For further information, visit http://www.pain-therapeutics.co.uk/prcom
Contact:
+44 (0)20 7827 6000
ldurneva@smi-online.co.uk
Twitter - @SMIpharm & #smipaintherapeutics
LinkedIn - SMi Pharma
Pain Therapeutics Conference | 21 - 22 May 2018 | London, UK
http://www.pain-therapeutics.co.uk/prcom
Contact
SMi Group
Luda Durneva
+44 (0)20 7827 6000
http://www.pain-therapeutics.co.uk/prcom
Luda Durneva
+44 (0)20 7827 6000
http://www.pain-therapeutics.co.uk/prcom
Contact
Categories